NASDAQ:VBLT
Delisted
Vascular Biogenics Ltd. Stock News
$0.156
+0 (+0%)
At Close: Jan 12, 2024
VBL Therapeutics: A Speculative Play With An Enticing Risk-Reward Profile
06:00am, Tuesday, 02'nd Mar 2021
While doing some speculative biotech window shopping, I came across VBL Therapeutics sitting on the sub-$100M market cap shelf. After a quick inspection, I am heading to the checkout.
Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee
01:08pm, Monday, 22'nd Feb 2021
Vascular Biogenics Ltd (NASDAQ: VBLT) announces results from the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 study of VB-111 in recurrent ova
VBLT Stock Price Increases Over 10% Pre-Market: Why It Happened
09:00am, Monday, 22'nd Feb 2021
The stock price of Vascular Biogenics Ltd (NASDAQ: VBLT) is trading at over 10% pre-market. This is why it happened.
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
07:00am, Wednesday, 27'th Jan 2021
TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company's proprietar
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
07:15am, Friday, 15'th Jan 2021
Agreement extends current cash runway to Q1 2023 Agreement extends current cash runway to Q1 2023
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
07:00am, Tuesday, 29'th Dec 2020
TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for
VBL Therapeutics Announces Insider Buying
07:00am, Monday, 07'th Dec 2020
TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-clas
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript
02:24pm, Monday, 16'th Nov 2020
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript
Vascular Biogenics: Q3 Earnings Insights
07:11am, Monday, 16'th Nov 2020
Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 14.29% year over year to ($0.1
VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:00am, Monday, 16'th Nov 2020
- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population wit
VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
07:00am, Thursday, 05'th Nov 2020
TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-clas
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
07:00am, Monday, 02'nd Nov 2020
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-clas
